[go: up one dir, main page]

BR9915142A - Novo material farmacêutico no formato de pérolas com liberação controlada, respectivo método de produção e formulação de múltiplas inidades compreendendo o mesmo - Google Patents

Novo material farmacêutico no formato de pérolas com liberação controlada, respectivo método de produção e formulação de múltiplas inidades compreendendo o mesmo

Info

Publication number
BR9915142A
BR9915142A BR9915142-1A BR9915142A BR9915142A BR 9915142 A BR9915142 A BR 9915142A BR 9915142 A BR9915142 A BR 9915142A BR 9915142 A BR9915142 A BR 9915142A
Authority
BR
Brazil
Prior art keywords
controlled release
layer
pharmaceutical material
formulation
multiple units
Prior art date
Application number
BR9915142-1A
Other languages
English (en)
Other versions
BRPI9915142B1 (pt
BRPI9915142B8 (pt
Inventor
Torkel Gren
Anders Ringberg
Martin Wikberg
Randy J Wald
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9915142(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/en
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of BR9915142A publication Critical patent/BR9915142A/pt
Publication of BRPI9915142B1 publication Critical patent/BRPI9915142B1/pt
Publication of BRPI9915142B8 publication Critical patent/BRPI9915142B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<B>"NOVO MATERIAL FARMACêUTICO NO FORMATO DE PéROLAS COM LIBERAçãO CONTROLADA, RESPECTIVO MéTODO DE PRODUçãO E FORMULAçãO DE MúLTIPLAS UNIDADES COMPREENDENDO O MESMO"<D> A presente invenção se refere a um material farmacêutico no formato de pérolas que compreende: (i) uma unidade de núcleo de um material substancialmente inerte solúvel em água ou expansível em água; (ii) uma primeira camada sobre a unidade de núcleo de um polímero substancialmente insolúvel em água; (iii) uma segunda camada cobrindo a primeira camada e contendo um ingrediente ativo; e (iv) uma terceira camada de polímero sobre a segunda camada efetiva, para liberação controlada do ingrediente ativo, em que a dita primeira camada é adaptada para controlar a penetração de água dentro do núcleo. é também divulgado pela presente invenção um método para produção de um material farmacêutico no formato de pérolas, de liberação controlada.
BRPI9915142A 1998-11-11 1999-11-11 novo material farmacêutico no formato de pérolas com liberação controlada, respectivo método de produção e formulação de múltiplas inidades compreendendo o mesmo BRPI9915142B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it

Publications (3)

Publication Number Publication Date
BR9915142A true BR9915142A (pt) 2001-08-07
BRPI9915142B1 BRPI9915142B1 (pt) 2015-08-25
BRPI9915142B8 BRPI9915142B8 (pt) 2021-05-25

Family

ID=20413266

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9915142A BRPI9915142B8 (pt) 1998-11-11 1999-11-11 novo material farmacêutico no formato de pérolas com liberação controlada, respectivo método de produção e formulação de múltiplas inidades compreendendo o mesmo

Country Status (40)

Country Link
US (1) US6911217B1 (pt)
EP (1) EP1128819B1 (pt)
JP (1) JP3616011B2 (pt)
KR (1) KR100467384B1 (pt)
CN (1) CN1169522C (pt)
AP (1) AP1323A (pt)
AR (1) AR027815A1 (pt)
AT (1) ATE247458T1 (pt)
AU (1) AU762410B2 (pt)
BG (1) BG65149B1 (pt)
BR (1) BRPI9915142B8 (pt)
CA (1) CA2350061C (pt)
CZ (1) CZ299582B6 (pt)
DE (1) DE69910604T2 (pt)
DK (1) DK1128819T3 (pt)
EA (1) EA005074B1 (pt)
EE (1) EE05232B1 (pt)
ES (1) ES2204193T3 (pt)
GE (1) GEP20022833B (pt)
HK (1) HK1040917B (pt)
HR (1) HRP20010333B1 (pt)
HU (1) HU226582B1 (pt)
ID (1) ID30039A (pt)
IL (1) IL142809A0 (pt)
IS (1) IS2370B (pt)
MA (1) MA25325A1 (pt)
MY (1) MY122195A (pt)
NO (1) NO331399B1 (pt)
NZ (1) NZ511430A (pt)
OA (1) OA11673A (pt)
PL (1) PL195780B1 (pt)
PT (1) PT1128819E (pt)
RS (1) RS49891B (pt)
SE (1) SE9803871D0 (pt)
SI (1) SI1128819T1 (pt)
SK (1) SK284758B6 (pt)
TW (2) TWI222879B (pt)
UA (1) UA57165C2 (pt)
WO (1) WO2000027364A1 (pt)
ZA (1) ZA200103575B (pt)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
AU784104B2 (en) * 1999-11-11 2006-02-02 Pfizer Health Ab Pharmaceutical formulation containing tolterodine and its use
CA2496806A1 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Oral liquid tolterodine composition
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
KR20050096147A (ko) * 2003-01-22 2005-10-05 피저 헬스 에이비 비뇨기 장애 치료용 톨테로딘 및 다른 항무스카린제의감소량 투여
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7410978B2 (en) 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
EP1680100A4 (en) 2003-11-04 2012-08-08 Supernus Pharmaceuticals Inc QUATERNARY AMMONIUM COMPOUNDS CONTAINING BIOAVAILABILITY ACTIVATORS
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (en) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
TW200637804A (en) * 2005-01-10 2006-11-01 Teva Pharma Substantially pure tolterodine tartrate and process for preparing thereof
WO2006130187A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic lactobacilli
ES2607988T3 (es) 2005-05-31 2017-04-05 Iams Europe B.V. Bifidobacterias probióticas felinas
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007083309A2 (en) 2006-01-18 2007-07-26 Intec Pharma Ltd. Method and apparatus for forming delivery devices for oral intake of an agent
EP3332788B1 (en) 2006-02-03 2025-10-15 Opko Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
KR100714058B1 (ko) * 2006-02-06 2007-05-02 한국유나이티드제약 주식회사 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
CN101516356A (zh) * 2006-02-24 2009-08-26 特瓦制药工业有限公司 琥珀酸美托洛尔缓释片及其制备方法
JP2009530397A (ja) * 2006-03-21 2009-08-27 テバ ファーマシューティカル インダストリーズ リミティド トルテロジンの調節された開放性製剤
EP1839649A1 (en) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Coated formulations for tolterodine
EP2007360B1 (en) * 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026766A1 (en) 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
EP2037936B1 (en) 2006-06-21 2014-06-11 Proventiv Therapeutics, LLC Method of treating and preventing secondary hyperparathyroidism
JP2008007458A (ja) * 2006-06-29 2008-01-17 Freunt Ind Co Ltd レイヤリング用核粒子とその製造方法
US8431593B2 (en) 2006-11-27 2013-04-30 H. Lundbeck A/S Heteroaryl amide derivatives
BRPI0808391A2 (pt) 2007-02-01 2014-07-08 Lams Company Método para diminuir a inflamação e o estresse em um mamífero, mediante o uso de antimetabólitos de glicose, abacate ou extratos de abacate.
CA2943032C (en) 2007-04-25 2019-05-07 Cytochroma Inc. Oral controlled release compositions comprising vitamin d compound and waxy carrier
EP3225243B1 (en) 2007-04-25 2025-09-03 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
EP2148684B1 (en) 2007-04-25 2013-01-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
WO2009003724A1 (en) * 2007-07-03 2009-01-08 Synthon B.V. Tolterodine bead
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
CA2923102C (en) * 2007-08-13 2019-10-15 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
US20090311317A1 (en) * 2008-05-14 2009-12-17 Capricorn Pharma Inc. Modified release tolterodine formulations
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
CA2769760A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
ES2643087T3 (es) 2010-03-29 2017-11-21 Ferring B.V. Composición farmacéutica de disolución rápida
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
EP2552484B1 (en) 2010-03-29 2020-01-08 Opko Ireland Global Holdings, Ltd. Methods and compositions for reducing parathyroid levels
EP2563123B1 (en) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el) 2011-07-27 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
NZ620897A (en) 2011-09-16 2016-07-29 Ferring Bv A fast dissolving pharmaceutical composition
US20140242158A1 (en) * 2011-09-30 2014-08-28 Astellas Pharma, Inc. Granular Pharmaceutical Composition
WO2014009241A1 (en) 2012-07-12 2014-01-16 Ferring B.V. Diclofenac formulations
HK1213178A1 (zh) * 2012-09-20 2016-06-30 Ohr Pharma, Llc 用於治疗剂的缓释的多层生物可降解的微粒
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
EP2968579B1 (en) * 2013-03-13 2020-04-15 Intervet International B.V. Stable bioactive substances and methods of making
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA3018328A1 (en) * 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2017146053A1 (ja) * 2016-02-23 2017-08-31 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤
SG10201913863TA (en) 2016-03-28 2020-03-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) * 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja) 1993-10-08 1995-04-21 Hitachi Ltd 情報通信装置
JP3453186B2 (ja) 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
BRPI9915142B1 (pt) 2015-08-25
HUP0105038A2 (en) 2002-06-29
SK284758B6 (sk) 2005-11-03
NO331399B1 (no) 2011-12-19
BG65149B1 (bg) 2007-04-30
ZA200103575B (en) 2002-05-03
NZ511430A (en) 2003-05-30
EE05232B1 (et) 2009-12-15
ES2204193T3 (es) 2004-04-16
PT1128819E (pt) 2003-12-31
PL195780B1 (pl) 2007-10-31
EA005074B1 (ru) 2004-10-28
BG105582A (en) 2001-12-29
EA200100538A1 (ru) 2001-10-22
JP3616011B2 (ja) 2005-02-02
DK1128819T3 (da) 2003-12-01
US6911217B1 (en) 2005-06-28
BRPI9915142B8 (pt) 2021-05-25
NO20012314L (no) 2001-07-09
KR100467384B1 (ko) 2005-01-24
PL348612A1 (en) 2002-06-03
NO20012314D0 (no) 2001-05-10
HU226582B1 (en) 2009-04-28
AP1323A (en) 2004-11-05
AU1436600A (en) 2000-05-29
DE69910604D1 (de) 2003-09-25
CZ299582B6 (cs) 2008-09-10
OA11673A (en) 2005-01-12
UA57165C2 (uk) 2003-06-16
CN1326339A (zh) 2001-12-12
EE200100254A (et) 2002-12-16
SI1128819T1 (en) 2003-12-31
CN1169522C (zh) 2004-10-06
CA2350061C (en) 2005-05-17
RS49891B (sr) 2008-08-07
MY122195A (en) 2006-03-31
SK6252001A3 (en) 2002-01-07
ATE247458T1 (de) 2003-09-15
HRP20010333B1 (en) 2004-10-31
MA25325A1 (fr) 2001-12-31
TWI267385B (en) 2006-12-01
IS5936A (is) 2001-05-09
EP1128819A1 (en) 2001-09-05
WO2000027364A1 (en) 2000-05-18
SE9803871D0 (sv) 1998-11-11
KR20010075695A (ko) 2001-08-09
AR027815A1 (es) 2003-04-16
GEP20022833B (en) 2002-11-25
CZ20011627A3 (cs) 2001-10-17
YU33101A (sh) 2003-10-31
HRP20010333A2 (en) 2003-04-30
AP2001002166A0 (en) 2001-06-30
IS2370B (is) 2008-06-15
HK1040917B (zh) 2005-05-27
HK1040917A1 (en) 2002-06-28
IL142809A0 (en) 2002-03-10
CA2350061A1 (en) 2000-05-18
TWI222879B (en) 2004-11-01
JP2003517446A (ja) 2003-05-27
AU762410B2 (en) 2003-06-26
EP1128819B1 (en) 2003-08-20
DE69910604T2 (de) 2004-06-24
ID30039A (id) 2001-11-01
HUP0105038A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
BR9915142A (pt) Novo material farmacêutico no formato de pérolas com liberação controlada, respectivo método de produção e formulação de múltiplas inidades compreendendo o mesmo
MXPA02004574A (es) Formulacion farmaceutica que contiene tolterodina y su uso.
AU679032B2 (en) Transdermal therapeutic system with galanthamine as active ingredient
WO2002003969A3 (de) Transdermales therapeutisches system mit hochdispersem siliziumdioxid
AU2001254711A1 (en) Sustained release vitamin composition
PT96579A (pt) Processo para a preparacao de um sistema terapeutico transdermico contendo 2-butil terc.-amino-1-(2&#39;-clorofenil)-etanol (tulobuterol) como ingrediente activo
KR910007548A (ko) 활성성분 플래스터, 그의 제조방법 및 용도
AU6517496A (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
PT93170A (pt) Processo para a preparacao de dispositivos distribuidores nomeadamente de capsulas contendo um ingrediente activo
DE69617732D1 (de) Transdermales estradiol/progestogen-pflaster und dessen herstellung
YU14394A (sh) Flaster sa aktivnom supstancom za davanje estradiola na kožu
AU4219497A (en) Sustained-release preparation utilizing thermal change and process for the production thereof
AU2001291526A1 (en) Sustained release composition containing clarithromycin
DE69713367D1 (de) Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit veränderter wirkstoffsfreisetzung, enthaltend eine matrix
ATE272395T1 (de) Präparationen zur kontrollierten freisetzung
EP1188436A3 (en) Percutaneously absorptive preparation
AU1393701A (en) Transdermal therapeutic system containing highly volatile active ingredients
AU687775B2 (en) Nitroglycerine-containing plaster, process for producing the same and its uses
AU684256B2 (en) Transdermal therapeutic system for administering physostigmin through the skin, and a method of producing the system
CA2020590A1 (en) Solid pharmaceutical composition containing a core and an outer layer
Hernandez et al. Effect of irrigation on the productivity of meloeiro in the Solteira Island regions- SP].
BR9902855A (pt) Formulação de papelão para palmilha de calçado com coloração lilás

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, COM BASE NOS ARTIGOS 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/11/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 11/11/2019

B25E Requested change of name of applicant rejected

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870210019319 DE26/02/2021 DEVIDO AO DESPACHO PUBLICADO NA RPI 2630 DE 01/06/2021.

B25H Request for change of headquarter rejected

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870210019319 DE26/02/2021 DEVIDO AO DESPACHO PUBLICADO NA RPI 2630 DE 01/06/2021.

B25B Requested transfer of rights rejected

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870210019329 DE 26/02/2021DEVIDO AO DESPACHO PUBLICADO NA RPI 2630 DE 01/06/2021.